Several new nucleosides with an oxetanosyl-N-glycoside group, named oxetanocins, were evaluated for their antiviral activities against varicella-zoster virus (VZV) in human embryo lung cells. 9-(2-deoxy-2-hydroxymethyl-,-D-erythro-oxetanosyl)guanine (OXT-G) and 9-(2-deoxy-2-hydroxymethyl-o-D-erythro-oxetanosyl)-2-aminoadenine were effective against not only thymidine kinase-positive (TK+) VZV (YS strain) but also thymidine kinase-negative (TK-) VZV (YSR strain), whereas carbocyclic OXT-G was effective against TK+ VZV but not against TK-VZV.
Several new nucleosides with an oxetanosyl-N-glycoside group, named oxetanocins, were evaluated for their antiviral activities against varicella-zoster virus (VZV) in human embryo lung cells. 9-(2-deoxy-2-hydroxymethyl-,-D-erythro-oxetanosyl)guanine (OXT-G) and 9-(2-deoxy-2-hydroxymethyl-o-D-erythro-oxetanosyl)-2-aminoadenine were effective against not only thymidine kinase-positive (TK+) VZV (YS strain) but also thymidine kinase-negative (TK-) VZV (YSR strain), whereas carbocyclic OXT-G was effective against TK+ VZV but not against TK-VZV.
[3H]OXT-G was incorporated into TK+ VZV-infected cells and TK-VZV-infected cells more than into mock-infected cells and was converted into the triphosphate form.
A new family of nucleoside analogs, oxetanocins, which have an oxetanosyl-N-glycoside group, has recently been developed (9, 10). Nishiyama et al. (4, 6) have shown that 9-(2-deoxy-2-hydroxymethyl-,3-D-erythro-oxetanosyl)adenine (OXT-A) and its derivatives, 9-(2-deoxy-2-hydroxymethyl-
guanine (OXT-G), have potent and selective activity against human cytomegalovirus and herpes simplex virus type 2 and that OXT-G is effective against systemic herpes simplex virus type 2 infections and cytomegalovirus infections in mice. A carbocyclic analog of oxetanocins has also been synthesized by Ichikawa et al. (2) , and the antiviral activity of the compound against herpes simplex virus type 1 and type 2 and human cytomegalovirus has been evaluated (5) . In the present study, we investigated the efficacy of OXT-A, 2-amino-OXT-A, OXT-G, 9-(2-deoxy-2-hydroxymethyl-p-Derythro-oxetanosyl)hypoxanthine (OXT-H), 9-(2-deoxy-2-hydroxymethyl -3-D-erythro-oxetanosyl)xanthine (OXT-X), and (+)-9-[(lR, 2R, 3S)-2,3-bis(hydroxymethyl)cyclobutyl] guanine (carbocyclic OXT-G) against varicella-zoster virus (VZV) in vitro.
OXT-A was prepared from a culture filtrate of Bacillus megaterium NK84-0218 (9), and 2-amino-OXT-A, OXT-H, OXT-X, OXT-G, and carbocyclic OXT-G were chemical and biological derivatives of OXT-A produced at the Research Laboratories, Nippon Kayaku Co., Ltd., Tokyo, Japan, and their chemical and physical characteristics were shown in our earlier reports (9, 10). 9-(2-Hydroxyethoxymethyl)guanine (acyclovir) was kindly provided by Burroughs Wellcome Laboratories (Research Triangle Park, N.C.). [4'-3H]OXT-G (101.1 GBq/mmol) was made to order by Nippon Kayaku Co. [methyl-3H]thymidine (3.07 TBq/mmol) was purchased from Radiochemical Centre, Amersham, England. Human embryo lung fibroblast (HEL) cells, strain HAIN-55 (7), were cultivated with Eagle's minimum essential medium supplemented with 10% fetal bovine serum. The YS strain (thymidine kinase positive [TK+] ) and the YSR strain (thymidine kinase negative [TK-]) of VZV were prepared and maintained in our laboratory as described previously (8) . Genetic analysis of the YSR strain and comparison with the complete DNA sequence of VZV (1) revealed that a one-point deletion of adenine at position 65298 (about the middle of the TK gene) caused a frameshift of the nucleotide sequence resulting in a change to the termination codon at the seventh codon downstream from the deletion site, i.e., the YSR strain has only a half molecule of the TK protein of the YS strain (3).
An assay for the antiviral activities (50% inhibitory doses) of compounds against VZV was carried out by the 50% plaque reduction method as described previously (8) . The inhibitory effects (50% effective doses) of compounds on cell growth was evaluated as described previously (11) . As shown in Fig. 1 and Table 1 , OXT-G and carbocyclic OXT-G had high selective antiviral activities against the YS (TK+) strain, although less than acyclovir, and 2-amino-OXT-A had moderate activity. The antiviral indexes (ratio of 50% effective dose for cells to 50% inhibitory dose for viruses) of OXT-G and carbocyclic OXT-G against the YS strain were similar and 1.5 to 2 times that of 2-amino-OXT-A. OXT-G and 2-amino-OXT-A had the same antiviral activities against the YSR (TK-) strain as against the YS strain, whereas carbocyclic OXT-G was approximately 10-fold less active. This phenomenon suggests that OXT-G and 2-amino-OXT-A may be initially phosphorylated to the monophosphate form by cellular TK, whereas carbocyclic OXT-G is phosphorylated by viral TK.
To confirm the above-mentioned suggestion and to obtain some information on the mechanism of antiviral activity of OXT-G, we examined the intracellular phosphorylation of [4'-3H]OXT-G in mock-infected, YS-infected, and YSRinfected HEL cells and compared it with the phosphorylation of [methyl-3H]thymidine by thin-layer chromatography as described in an earlier report (12) . The positions of 5' phosphates of nucleosides were estimated on the basis of the migration patterns of thymidine, dTMP, dTDP, dTTP, OXT-G, OXT-G monophosphate, OXT-G diphosphate, and OXT-G triphosphate by detection with a UV light lamp. uptake and turnover of OXT-G in mock-infected cells were moderate (Fig. 2) . In the above-described studies, we found that OXT-G and carbocyclic OXT-G were the most potent compounds against VZV. Notably, OXT-G had the same antiviral activity against the YSR (TK-) strain as against the YS (TK+) strain. In agreement with our results, Nishiyama et al. (4) also reported that OXT-G had potent and selective activity against human cytomegalovirus, which does not encode viral TK, and TK+ and TK-herpes simplex virus type 2. These results and the data shown in Fig. 2 strain), whereas in mock-infected cells under monolayer conditions, the incorporation and metabolism of nucleosides may be reduced. Also, the high antiviral index of OXT-G suggests that OXT-G triphosphate may have a higher affinity for viral DNA polymerase than for cellular DNA polymerase. In summary, OXT-G is a potent and selective inhibitory compound in vitro against several herpesviruses which are normally insensitive or may have become insensitive to currently available antiherpesvirus drugs. 
